

**Appl. No.** : 10/660,357  
**Filed** : September 10, 2003

## **AMENDMENTS TO THE SPECIFICATION**

**Please amend the specification to replace the Sequence Listing as originally filed with the Substitute Sequence Listing attached herewith.**

**Please amend the paragraph beginning on page 4, line 16 as follows.**

One embodiment of the invention is a method of inhibiting tumor growth in an animal that includes: selecting an animal in need of treatment for a tumor; providing a monoclonal antibody comprising a heavy chain amino acid, wherein the antibody has an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 5, 9, 13, 17, 21, 25, 29, 33 and 37, and wherein the monoclonal antibody binds MUC18; and contacting the tumor with an effective amount of said antibody, wherein the contacting results in inhibited proliferation of said cells.

**Please amend the paragraph beginning on page 4, line 23 as follows.**

Another embodiment of the invention is a method of inhibiting cell invasion associated with melanoma by: selecting an animal in need of treatment for melanoma; providing a monoclonal antibody having a heavy chain amino acid, wherein the antibody has an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 5, 9, 13, 17, 21, 25, 29, 33 and 37, and wherein the monoclonal antibody binds MUC18; and contacting the melanoma with an effective amount of the antibody, wherein the contacting results in inhibited cell invasion.

**Please amend the paragraph beginning on page 4, line 30 as follows.**

Yet another embodiment of the invention is a method of increasing survival of an animal having a metastatic tumor. This method includes: selecting an animal in need of treatment for a metastatic tumor; providing a monoclonal antibody comprising a heavy chain amino acid, wherein the antibody has an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 5, 9, 13, 17, 21, 25, 29, 33 and 37, and wherein the monoclonal antibody binds MUC18; and contacting said animal with an effective amount of the antibody, wherein the contacting results in inhibited metastasis of the tumor resulting in increased survival of the animal.

Appl. No. : 10/660,357  
Filed : September 10, 2003

**Please amend the paragraph beginning on page 10, line 3 as follows.**

Figure 28 represents an alignment between the amino acid sequence of the variable region of the heavy chain of anti-MUC18 antibody, c6.12 (SEQ ID NO: 81), and the amino acid sequence encoding the V4-31 region (SEQ ID NO: 65) of the germline V<sub>H</sub> gene used. The consensus sequence (SEQ ID NO: 66) is represented below the alignment.

**Please amend the paragraph beginning on page 10, line 7 as follows.**

Figure 29 represents an alignment between the amino acid sequence of the variable region of the light chain of anti-MUC18 antibody, c6.12 (SEQ ID NO: 82), and the amino acid sequence encoding the L2 region (SEQ ID NO: 67) of the germline V<sub>k</sub> gene used. The consensus sequence (SEQ ID NO: 68) is represented below the alignment.

**Please amend the paragraph beginning on page 11, line 11 as follows.**

Figure 36 represents a summary of the sequences comprising the V, D, J and resulting N recombination regions of the MUC18 antibody clones identified in the present invention. The D region sequences for MUC18 antibody clones A15-3.45 (SEQ ID NO: 85), A15-6.1 (SEQ ID NO: 86), A15-6.2 (SEQ ID NO: 87), A15-6.9 (SEQ ID NO: 88), A15-6.11 (SEQ ID NO: 89), and A15-6.12 (SEQ ID NO: 90) are shown.

**Please amend the paragraph beginning on page 32, line 25 as follows.**

The primers used for the amplification of the ECD of MUC18 were as follows:

Forward primer: 5'-ATATTACGAATTCACTTGCGTCTCGCCCTCCGG-3' (SEQ ID NO: ~~40~~ 83)

Reverse primer: 5'-CAGCTTAGAGCTAGCCGGCTCTCCGGCTCCGGCA-3' (SEQ ID NO: ~~44~~ 84)